F 652

Drug Profile

F 652

Alternative Names: F-652; P-652; Recombinant Human Interleukin-22 IgG2-Fc

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Generon (Shanghai) Corporation
  • Class Anti-inflammatories; Interleukins; Recombinant proteins
  • Mechanism of Action STAT3 transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis
  • No development reported Graft-versus-host disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In volunteers) in Australia (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Alcoholic-hepatitis(In volunteers) in Australia (SC, Injection)
  • 08 Mar 2016 F 652 is available for licensing - http://www.generonbiomed.com/html/en/index.php?ac=article&at=list&tid=35
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top